CISEN(SH:603367)2021-08-18 16:00Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,831,553,935.01, representing a 10.46% increase compared to ¥1,658,181,213.32 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥182,695,680.05, a slight increase of 1.69% from ¥179,665,880.84 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥169,574,758.16, which is a 3.72% increase from ¥163,488,505.64 in the same period last year[20]. - The basic earnings per share remained stable at ¥0.40, unchanged from the previous year[22]. - The diluted earnings per share also remained at ¥0.40, consistent with the previous year[22]. - The company achieved a total operating revenue of CNY 1.83 billion in the first half of 2021, an increase of 10.46% compared to the same period last year[38]. - The net profit attributable to shareholders was CNY 183 million, reflecting a year-on-year increase of 1.69%[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 170 million, up by 3.72% year-on-year[38]. - Operating costs rose to CNY 771 million, an increase of 15.60% compared to the previous year[39]. - The company reported a net cash flow from operating activities of CNY 37.78 million, down 57.04% from the previous year[39]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,994,052,203.32, down 2.78% from ¥6,165,710,473.50 at the end of the previous year[22]. - The total assets decreased from RMB 6,165,710,473.50 to RMB 5,994,052,203.32, a decline of approximately 2.77%[145]. - Current assets totaled RMB 3,695,727,658.95, down from RMB 3,950,229,934.55, representing a decrease of about 6.43%[145]. - Total liabilities decreased from RMB 1,363,765,384.23 to RMB 1,126,088,575.98, a reduction of about 17.38%[147]. - The company's equity decreased to CNY 4,542,000,211.65 from CNY 4,567,438,502.53, a decrease of about 0.6%[154]. Cash Flow - The net cash flow from operating activities decreased significantly by 57.04% to ¥37,783,957.82 from ¥87,950,865.39 in the previous year[20]. - Cash and cash equivalents at the end of the period were CNY 358 million, a decrease of 45.86% compared to the previous year[44]. - The total cash inflow from operating activities was ¥1,638,677,222.55, an increase from ¥1,510,547,727.31 in the same period of 2020[169]. - The cash paid for purchasing goods and services was 322,686,157.12 RMB, compared to 300,835,340.46 RMB in the previous year[176]. Research and Development - The company has established advanced R&D centers and partnerships with high-end research institutions, enhancing its capability to develop new products and technologies[33]. - Research and development expenses decreased by 5.14% to CNY 158 million[39]. - Research and development expenses for the first half of 2021 were CNY 157,862,143.19, slightly down from CNY 166,421,126.09 in the previous year, a decrease of approximately 5.1%[158]. Market Position and Products - The company has a diverse product structure with over 400 drug approval numbers, covering various forms including injections, tablets, and capsules, which provides a competitive advantage in the pharmaceutical market[33]. - The pharmaceutical industry in China is expected to exceed ¥5.3 trillion in sales revenue by 2025, indicating significant growth potential for the company[29]. - The company successfully obtained production licenses for energy drinks and special medical foods, laying the foundation for future sales[30]. - The company's product "Esomeprazole Magnesium Enteric-coated Capsules" has been approved for sale in the U.S., marking a significant milestone for its international market entry[30]. Environmental Compliance - The company has installed activated carbon treatment equipment for exhaust emissions from various production processes, ensuring compliance with discharge standards[70]. - The company has a quarterly self-monitoring plan for wastewater, including parameters such as pH, chemical oxygen demand, and total nitrogen[78]. - The actual emissions of VOCs were recorded at 5.91 mg/Nm³, well below the limit of 60 mg/Nm³[85]. - The company has been proactive in environmental protection, with no incidents reported during the reporting period[79]. Shareholder Information - The company has 30,125 ordinary shareholders as of the end of the reporting period[125]. - The largest shareholder, Chenxin Technology Group Co., Ltd., holds 165,673,200 shares, representing 36.54% of the total shares[126]. - A total of 800,000 restricted stock units were granted to executives during the reporting period, with each executive receiving 200,000 shares[136]. Risks and Challenges - The company faces risks in drug research and development, including high investment and long development cycles, which may lead to mismatched returns and potential losses[50]. - The company is at risk of losing core technical personnel, which could adversely affect its profitability[53]. - Environmental risks are present due to the company's status as a key pollutant discharger, necessitating compliance with stricter environmental regulations[53].